Details
Liquid biopsy is transforming how laboratories and clinicians approach comprehensive genomic profiling (CGP)—offering a faster, less invasive path to the molecular insights that guide treatment decisions. This three-part webinar series, developed in partnership with The Pathologist, explores liquid biopsy from multiple angles: the clinical rationale and evidence base, the operational realities of implementing large-panel assays in decentralized lab settings, and real-world cases. Whether you are evaluating liquid biopsy for your institution or deepening an existing program, this series delivers practical guidance from experts on the front lines of genomic medicine.
Webinar 1
Liquid biopsy in lung and breast cancer: Real-world tumor profiling and clinical insights
On demand
Liquid biopsy is gaining traction across cancer pathways—particularly when tissue is limited or results are needed quickly. This session provides a foundational look at liquid biopsy comprehensive genomic profiling (CGP) and how it complements tissue-based testing, followed by a real-world perspective from Wales on integrating liquid biopsy into routine lung cancer workflows and using ESR1 testing in blood samples from breast cancer patients.
What you will learn:
- How liquid biopsy CGP complements tissue testing and where it adds the most clinical value
- How earlier molecular insights can support faster, more informed treatment decisions
- Real-world workflow integration experience, including ESR1 testing in breast cancer
- Common operational and clinical challenges during liquid biopsy adoption—and strategies to address them
Speakers
Rachel Dodds
Principal Clinical Scientist
All Wales Medical Genomics Service
Pilar Ramos
Sr Manager, Medical Affairs Europe
Illumina
Webinar 2
Implementation of a large liquid biopsy genomic profiling assay in a decentralized setting
Thursday, April 30, 2026 | 11 AM / 8 AM (PT)
Large-panel (300+ genes) liquid biopsy assays are making comprehensive genomic profiling more accessible than ever—even for laboratories that have historically relied on send-out testing. Improvements in library preparation, decreasing cost per sample, and compatibility with mid-throughput sequencing instruments are changing what is operationally feasible in-house. In this session, Dr. Gang Zheng, MD, PhD, shares Mayo Clinic's experience implementing the TSO 500 ctDNA v2 assay for CGP research, including performance data, reproducibility, and practical considerations for bringing large-panel liquid biopsy testing in house.
What you will learn:
- What liquid biopsy options Mayo Clinic offers and the rationale behind bringing a large-panel assay in house
- Performance of TSO 500 ctDNA v2 across key variant classes—SNVs, Indels, CNVs, rearrangements, and large gene signatures—in blood and cerebrospinal fluid
- Analytical accuracy, reproducibility, and approaches to CHIP detection and filtering
- Concordance to solid tumor CGP (FFPE tissue) and comparative performance versus a liquid biopsy send-out assay
Speaker
Gang Zheng, MD, PhD
Co-Director, Mayo Clinical Genomics Laboratory
Professor, Dept of Laboratory Medicine and Pathology
Webinar 3
Coming in June 2026
Details for the third session in this series will be announced soon. Check back for speaker information, learning objectives, and registration.
- Date & Time
- 1 Jun. 2026
- Final date for webinar 3 TBD
- Topic
- Cancer research, Oncology